Referred to the House Committee on Ways and Means.
The bill adds a new Internal Revenue Code section (139J) that excludes from gross income amounts paid to individuals (or their dependents) for participating in approved clinical trials, including compensation and reimbursement of reasonable and necessary expenses. It defines “approved clinical trial” by reference to section 2709(d)(1) of the Public Health Service Act and “dependent” by reference to section 152 of the tax code.
Fiscal cost vs. public-health benefit: liberals emphasize access and participation gains; conservatives emphasize new tax expenditure and unknown revenue loss.
Relative to its intended legislative type, this bill establishes a clear and narrowly scoped substantive change to the tax code and program-eligibility rules, with adequate statutory placement and basic definitions but limited operational, fiscal, and oversight detail.
The bill adds a new Internal Revenue Code section (139J) that excludes from gross income amounts paid to individuals (or their dependents) for participating in approved clinical trials, including compensation and reimbursement of reasonable and necessary expenses.
It defines “approved clinical trial” by reference to section 2709(d)(1) of the Public Health Service Act and “dependent” by reference to section 152 of the tax code.
The exclusion would apply to amounts paid after December 31, 2025.
On content alone the bill is plausible: it is targeted, administrable, and addresses a non-controversial goal (encouraging clinical trial participation). Those features increase the chances it could be adopted, especially as part of a broader health or tax bill. However, it creates an uncosted tax expenditure and imposes a federal constraint on program eligibility determinations, which may prompt scrutiny, CBO scoring concerns, and negotiation hurdles that reduce the chance of standalone enactment.
Relative to its intended legislative type, this bill establishes a clear and narrowly scoped substantive change to the tax code and program-eligibility rules, with adequate statutory placement and basic definitions but limited operational, fiscal, and oversight detail.
Fiscal cost vs. public-health benefit: liberals emphasize access and participation gains; conservatives emphasize new tax expenditure and unknown revenue loss.
These are examples from the analysis, not a ranked list of the most-affected groups.
Fiscal cost vs. public-health benefit: liberals emphasize access and participation gains; conservatives emphasize new tax expenditure and unknown revenue loss.
A liberal/left-leaning person is likely to view the bill favorably overall because it reduces financial barriers that can keep low-income people from enrolling in clinical trials and it preserves safety-net eligibility by excluding those payments from means-testing.
They will likely appreciate measures that increase access, diversity, and representation in clinical research.
At the same time they may be concerned about potential for exploitation of vulnerable people and will want safeguards to ensure payments are not coercive and that trials meet strong ethical standards.
A centrist/moderate is likely to be cautiously supportive, seeing the bill as a targeted, practical change to reduce administrative barriers to clinical trial participation and protect benefits eligibility.
They will want more information about fiscal impacts and administrative feasibility, and may favor technical fixes or reporting requirements to reduce fraud or gaming.
They will weigh public-health benefits against any new tax expenditure.
A mainstream conservative is likely to be mixed to somewhat opposed.
They may favor reducing taxes and lowering barriers to voluntary clinical research participation, but will be concerned about creating a new tax expenditure, widening exemptions that complicate benefits administration, and potential for fraud or federal overreach.
They will want tighter limits, fiscal offsets, and strong verification to prevent abuse.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is plausible: it is targeted, administrable, and addresses a non-controversial goal (encouraging clinical trial participation). Those features increase the chances it could be adopted, especially as part of a broader health or tax bill. However, it creates an uncosted tax expenditure and imposes a federal constraint on program eligibility determinations, which may prompt scrutiny, CBO scoring concerns, and negotiation hurdles that reduce the chance of standalone enactment.
The bill has not accumulated any surfaced votes yet.
Fiscal cost vs. public-health benefit: liberals emphasize access and participation gains; conservatives emphasize new tax expenditure and u…
On content alone the bill is plausible: it is targeted, administrable, and addresses a non-controversial goal (encouraging clinical trial p…
Relative to its intended legislative type, this bill establishes a clear and narrowly scoped substantive change to the tax code and program-eligibility rules, with adequate statutory placement and basic definitions but…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.